搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
thedailyupside
10 小时
Novo Nordisk May Have Another Blockbuster on its Hands
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
23 小时
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
2 天
Blair Chief Clerk resigns for second time in four months
Blair County's Chief Clerk and County Administrator, Sherry Socie, has resigned, again.
pulmonologyadvisor
2 天
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
devdiscourse
3 天
Novo Nordisk's Breakthrough in Obesity Treatment: Amycretin Shows Promising Results
Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...
Medscape
3 天
Obesity Medications: Who Needs Priority Access
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
4 天
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
4 天
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
4 天
Insurance coverage and type of employment shape inequities in access to semaglutide
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...
来自MSN
4 天
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
5 天
Taking Ozempic for weight loss? You might find other benefits, too - and a few risks
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.
5 天
Are we nearing peak obesity as weight loss drugs gain popularity?
As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈